Pelthos launches Moms Against Molluscum campaign for skin infection

DURHAM, N.C. - Pelthos Therapeutics Inc. (NYSE American:PTHS), a small-cap biotech company with a market capitalization of $82.56 million, announced Thursday the launch of Moms Against Molluscum, a movement aimed at connecting parents and caregivers dealing with molluscum contagiosum, a highly contagious viral skin infection. The company’s stock has shown remarkable momentum, delivering a 323.4% return year-to-date, according to InvestingPro data.

The initiative includes a website, MomsAgainstMolluscum.com, offering resources and information about treatment options, including the company’s recently launched ZELSUVMI (berdazimer) topical gel, 10.3%. Wall Street analysts maintain a strong buy consensus on the stock, with price targets ranging from $50 to $60, suggesting significant upside potential from current levels.

Molluscum contagiosum affects an estimated 16.7 million Americans, with up to 6 million new cases annually, primarily in children. The infection can spread within households, with approximately 41% of children transmitting it to another household member.

"I have seen firsthand the toll molluscum takes on parents, especially when it spreads within families," said Stephen W. Stripling, MD, Pediatrician at The Medical University of South Carolina, according to the press release.

ZELSUVMI, which received FDA approval as a Novel Drug in January 2024, is described as the first prescription therapy approved for at-home treatment of molluscum in patients one year and older. Pelthos launched the medication in July 2025.

The infection presents as raised, flesh-colored or red bumps that can appear anywhere on the body and may persist for months to years if left untreated. Complications can include itching, secondary bacterial infections, and atopic dermatitis.

The company stated it is running an educational campaign on social media to raise awareness about the condition and its treatment options.

Pelthos Therapeutics is a biopharmaceutical company focused on commercializing therapeutic products for patients with unmet treatment needs, according to the press release statement. While the company operates with moderate debt levels, InvestingPro analysis indicates current financial health challenges, with additional insights available to subscribers. Get access to 8 more exclusive ProTips and comprehensive financial metrics to make informed investment decisions.

In other recent news, Pelthos Therapeutics has caught the attention of the investment community following its formation through a merger between Channel Therapeutics and a subsidiary of LGND. This merger, which took place in July, brought together rights to the FDA-approved ZELSUVMI treatment under the Pelthos Therapeutics umbrella. In a notable development, Oppenheimer has initiated coverage on Pelthos Therapeutics with an Outperform rating, setting a price target of $50.00. This rating reflects a positive outlook from the analyst firm. These recent developments highlight significant corporate restructuring and analyst interest in Pelthos Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.